Despite the high number of reviews aiming to prove how the modulation of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome, the main producer of IL-1β, might be beneficial in COVID-19 patients [5–7], only a few studies have been conducted to verify that hypothesis [8–10], and they provided limited data to support the use of NLRP3 inhibitor compounds in COVID-19 patients. The gene discussed is NLRP3; the disease is COVID-19.